Meet BrosMed at SOLACI 2025
Release time:
2025-07-30
Save the Date August 6–8, 2025 and visit us at Booth #9 to explore more highlights!
BrosMed Medical is delighted to participate in SOLACI 2025 from August 6 to 8, 2025 at Expo Santa Fe, Mexico City, Mexico.
We can’t wait to engage with the masters and partners there, as well as showcase our cutting-edge solutions for Complex and High-Risk Coronary Interventions (CHIP), including:
RevoEdge™ High Pressure Cutting Balloon Dilatation Catheter:
The new cutting design redefines cutting technology;
Pronavi™ Microcatheter:
Two low-profile options: 1.7F &1.9F, 135cm length for antegrade,
150cm & 162cm length for retrograde;
Alveo™ HP CTO Balloon Dilatation Catheter:
Smallest ø 0.75mm CTO Balloon in the world;
Wedge™ NC Scoring PTCA Balloon Dilatation Catheter:
Safe and controlled lesion preparation;
POT™ PTCA NC Balloon Dilatation Catheter:
Dedicated Balloon for POT and DOT Technique;
Eagle™ 0.014'' Guidewire:
First-ever 3D pre-shaped guidewire with exceptional tip design.
We warmly invite you to visit Booth 9 to meet our expert team, experience our latest technologies, and see how BrosMed is shaping the future of CHIP PCI and beyond.
We look forward to welcoming you to SOLACI 2025!
Next Article
Join Us!
Please fill out this form and we will get in touch within 24 hours.
* Note: Please be sure to fill in the information accurately and keep the communication unblocked. We will get in touch with you as soon as possible.
More news
BrosMed Announces Canadian Approval of RevoEdge™ High-Pressure Cutting Balloon
BrosMed Medical today announced Canadian regulatory approval of the RevoEdge™ High-Pressure Cutting Balloon Dilatation Catheter, expanding the company’s presence in North America and marking another milestone in the global commercialization of its specialty coronary portfolio.
2026-09-14
BrosMed Announced CE MDR Approval of VascuGlide™ Microcatheter System
June 15, 2026-BrosMed is pleased to announce that the VascuGlide™ Microcatheter System has received CE MDR certification, marking another significant milestone in the company's commitment to advancing peripheral intervention solutions.
2026-06-18
